Table 3 Key study measures
Area of assessment | Variable measured | Measure source |
|---|---|---|
Demographics | Name, address, phone, email, social media, locator info, Age, race, gender, sexual orientation, marital status, income, education, employment, housing, health insurance, language | CDEs [33] |
COVID risk | Exposure to SARS-CoV-2 | CDEs |
Comorbidities | ||
Disabilities | ||
COVID symptoms | ||
COVID-19 attitudes/beliefs/knowledge | COVID-19 knowledge | NIH PhenX Toolkit [32] |
Attitudes about COVID-19 vaccine | CDEs | |
Attitudes about COVID-19 testing | ||
Confidence in government and the healthcare system | PhenX Toolkit | |
Social determinants of health | Services accessed in the past 30 days/week/2 weeks | Treatment Service Review (TSR) [35] |
Housing | Added from TSR and CDEs | |
Food access | PhenX Toolkit | |
Health care access | CDEs | |
Use of technology (including telehealth) | PhenX Toolkit/CDEs | |
Social support | MOS Social Support [36] | |
Pandemic impact | PhenX Toolkit | |
COVID-19 outcomes | Adherence to prevention guidelines | PhenX Toolkit |
Adherence to treatment guidelines | CDEs | |
First COVID-19 test completion date | – | |
Second COVID-19 test completion date | ||
COVID-19 test 1 result | ||
COVID-19 test 2 result | ||
First stage intervention completion date | ||
Second stage intervention completion date | ||
Mental health and drug use | Overall mental health | CDEs |
Trauma | CDEs and PTSD Checklist [37] | |
Self-efficacy | General Self-Efficacy Scale (GSE-6) [38] | |
Substance misuse | CDEs | |
Client satisfaction | End of treatment questionnaire | Developed by us |
IRB | Anticipated adverse events | |
Serious adverse events |